Responding to the growing need for new antibiotics, Merck & Co Inc has reached an agreement to acquire Cubist Pharmaceuticals Inc for $9.5 billion. Cubist’s pipeline has new treatments for both Methicillin-resistant Staphylococcus aureus and Clostridium difficile infections.
